Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AGY-94806; Cutamesine dihydrochloride; Msc-1; SA-4503

Latest Information Update: 23 Dec 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Santen Pharmaceutical
  • Developer Ms Science; Santen Pharmaceutical
  • Class Antidepressants; Neuroprotectants; Nootropics; Piperazines; Small molecules
  • Mechanism of Action Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis; Retinitis pigmentosa
  • Discontinued Major depressive disorder; Stroke; Vascular dementia

Most Recent Events

  • 10 Mar 2014 Preclinical trials in Amyotrophic lateral sclerosis in Japan (PO)
  • 01 Dec 2010 Cutamesine is still in phase IIa development for Stroke and Depression
  • 12 Mar 2008 M's Science Corporation and Eisai enter into an option agreement for SA 4503
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top